ASGCT News

ASGCT Releases Anti-Harassment Policy

Dr. Nicole K. Paulk, Ph.D. - August 03, 2018

The fields of gene and cell therapy are strongest when all members are supported by positive, safe, and healthy work environments. To reinforce a healthy environment for all, the ASGCT Trainee and Executive committees established a new mandatory anti-harassment and non-discrimination policy for all ASGCT events.

The fields of gene and cell therapy will be strongest when all members are supported by positive, safe, and healthy work environments. To reinforce a healthy environment for all, the inaugural Trainee Committee of the American Society of Gene & Cell Therapy (ASGCT) worked together with the Executive Committee to establish a new mandatory anti-harassment and non-discrimination policy for all ASGCT events. Our hope is that this new policy will prevent incidents of harassment and discrimination, remove barriers to reporting incidents, and maintain the high quality of scientific discourse that we have come to expect at ASGCT events.

Read the full text of the ASGCT Anti-Harassment Policy

We ask that you join us in making sure that all ASGCT events are a safe and welcoming environment for everyone. Improving the climate within our society and at our meetings is an endeavor that needs the engagement and participation of all members and non-member attendees alike. If we all are aware of our policies, and have an open dialog about expectations of conduct in conference settings, we can improve the collective experience at our meetings.

Related Articles

ASGCT News

Submit Your Annual Meeting Abstracts through Jan. 31, 2025

Send us your research for presentation at #ASGCT2025. - November 11, 2024
ASGCT News

Interius CEO To Present on in vivo CAR-T at ASGCT Cancer Conference

Register for Advancing Gene and Cell Therapies for Cancer - August 09, 2024
ASGCT News

Dr. Terence Flotte Calls for CGT Investment and Collaboration During Congressional Testimony

Read Dr. Flotte's testimony + watch the hearing - February 29, 2024
ASGCT News

Mohamed Abou-el-Enein Appointed Editor of Molecular Therapy Methods and Clinical Development

Dr. Abou-el-Enein began five-year term Jan. 1. - January 04, 2024